Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Inventory (2019 - 2025)

Historic Inventory for Karyopharm Therapeutics (KPTI) over the last 7 years, with Q4 2025 value amounting to $4.0 million.

  • Karyopharm Therapeutics' Inventory fell 1479.22% to $4.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.0 million, marking a year-over-year decrease of 1479.22%. This contributed to the annual value of $4.0 million for FY2025, which is 1479.22% down from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Inventory is $4.0 million, which was down 1479.22% from $4.0 million recorded in Q3 2025.
  • Karyopharm Therapeutics' Inventory's 5-year high stood at $5.0 million during Q2 2025, with a 5-year trough of $2.8 million in Q1 2024.
  • For the 5-year period, Karyopharm Therapeutics' Inventory averaged around $3.9 million, with its median value being $3.9 million (2021).
  • Its Inventory has fluctuated over the past 5 years, first skyrocketed by 22103.09% in 2021, then tumbled by 2795.93% in 2023.
  • Karyopharm Therapeutics' Inventory (Quarter) stood at $4.1 million in 2021, then grew by 2.87% to $4.2 million in 2022, then dropped by 27.96% to $3.0 million in 2023, then surged by 55.73% to $4.7 million in 2024, then dropped by 14.79% to $4.0 million in 2025.
  • Its last three reported values are $4.0 million in Q4 2025, $4.0 million for Q3 2025, and $5.0 million during Q2 2025.